Solid-state forms of stat3 inhibitors and methods of use thereof
WO2025137366A3 Publication Date: 2025-08-21TVARDI THERAPEUTICS INC
2 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2024/061149
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-20
- Filing Date
- 2024-12-19
- Publication Date
- 2025-08-21
AI Technical Summary
Technical Problem
Current treatments for cancer, fibrosis, and inflammatory diseases often struggle with efficacy and specificity, particularly in targeting the STAT3 signaling pathway which is central to these conditions.
Method used
The development of solid-state forms of a compound represented by Formula (I), which acts as a STAT3 inhibitor, formulated into pharmaceutical compositions to effectively inhibit STAT3 activity, thereby treating, preventing, or reducing the severity of cancer, fibrosis, and inflammatory diseases.
Benefits of technology
The solid-state forms of the compound effectively inhibit STAT3, leading to therapeutic benefits in treating cancer, fibrosis, and inflammatory diseases by modulating the immune response and reducing immunosuppressive factors.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided herein, in some embodiments, are solid-state forms of a compound represented by Formula (I), as free acid or base, or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions comprising one or more solid-state forms of a compound represented by Formula (I), as free acid or base, or a pharmaceutically acceptable salt or solvate thereof, and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art